

Starting your patients on TAVNEOS[®] (avacopan)

Amgen's TAVNEOS[®] Connect program
can help your patients access therapy



87% of insured patients,
regardless of formulary
coverage, **were approved**
for TAVNEOS[®]^{1,*}



Time to fill is 7 days
or less for most
patients, regardless of
insurance approval^{2,†}



^{*}Based on patient approval rates from October 2021 through December 2022.¹

[†]Based on patient Start Forms from October 2021 through March 2023.²

AMGEN[®]

For questions, call the TAVNEOS[®] Connect Team at **1-833-TAVNEOS (1-833-828-6367)**
and choose option 2, Monday through Friday from 8 AM to 8 PM ET

TAVNEOS® Connect offers a wide range of support for patients*

The TAVNEOS® Connect Team is here to help your patients access TAVNEOS®.

TAVNEOS® Connect can

- Help patients understand insurance benefits and assist eligible commercially insured patients with their copay*
- Offer resources to help patients learn about TAVNEOS®
- Connect patients with communities that can support them during their treatment journey
- Provide medication to eligible patients who do not have insurance and who meet other program criteria




TAVNEOS® Connect Quick Start Program*,†

For newly prescribed TAVNEOS® patients, this program can **initially provide up to a 30-day supply**:

- For eligible patients whose insurance plan requires a prior authorization and you believe a delay in therapy could lead to negative clinical outcomes
- For eligible patients being discharged from an inpatient setting to support continuity of care

To enroll your patients:



After the pharmacy speaks to your patient to coordinate delivery, the Quick Start supply will be shipped **directly to your patient's home**. See complete submission details on the last page.

Helpful tips for patients enrolling in the TAVNEOS® Connect Quick Start Program

- Ensure all required fields on the Start Form are completed. Missing information can cause delays
- Send a fully completed Start Form with prescription by 12 PM ET (not including holidays or weekends) to increase the likelihood of same day medication shipping to patients

For patients transitioning from an inpatient setting:

- Include the contact information for the outpatient healthcare provider (HCP) managing the patient's condition
- If the patient has designated an alternate contact person, include their information for faster communications

For questions, call the TAVNEOS® Connect Team at **1-833-TAVNEOS (1-833-828-6367)** and choose option 2, Monday through Friday from 8 AM to 8 PM ET

TAVNEOS® Connect Copay Program^{*,†}

The TAVNEOS® Connect Copay Program helps eligible commercially insured patients reduce out-of-pocket costs.

Your patient's copay may be as little as:

\$0 for a month supply

- The TAVNEOS® Connect Team and Network Specialty Pharmacies work together to enroll all patients who are eligible for copay support
- The Specialty Pharmacy will contact your patient directly each month to coordinate shipment to your patient's home

TAVNEOS® Patient Assistance Program^{*}

For eligible patients who are uninsured or are unable to afford their medication, the Patient Assistance Program may help provide access to TAVNEOS®.

- Once your patient's Start Form is submitted, if your patient is unable to access TAVNEOS® after completing the prescription process, they may complete a Patient Assistance Program application and undergo screening by the TAVNEOS® Connect Team
- Patients must meet eligibility criteria related to age, diagnosis, income, residency, and insurance status

^{*}TAVNEOS® Connect services are available for adult patients whose diagnosis is aligned with the FDA-approved indication for TAVNEOS®. Additional eligibility criteria may apply.

[†]Terms, conditions, and program maximums apply. Other restrictions may apply. This program is not open to patients receiving prescription reimbursement under any federal, state or government funded healthcare program, or for cash patients. This is not insurance or a guarantee of payment. No cash value. Void where prohibited by law.



For questions, call the TAVNEOS® Connect Team at **1-833-TAVNEOS (1-833-828-6367)** and choose option 2, Monday through Friday from 8 AM to 8 PM ET

Choose ONE submission option to get your patient started on TAVNEOS®



Submit Start Form via fax (with the prescription section completed or eRx), OR



ePrescribe to a Network Specialty Pharmacy, OR



Submit online enrollment at tavconnectrxhcp.iassist.com

The Start Form is available from your Amgen representative or at tavneospro.com/tavneos-connect.

IF PATIENT NEEDS QUICK START

Fax completed Start Form to the
TAVNEOS® Connect Team



OR

IF PATIENT DOES NOT REQUIRE QUICK START

Fax completed Start Form and/or ePrescribe to
ONE of the Network Specialty Pharmacies



Phone:	1-833-TAVNEOS (828-6367), Option 2, then Option 1	1-833-TAVNEOS (828-6367), Option 2, then Option 2	1-833-TAVNEOS (828-6367), Option 2, then Option 3
Fax:	1-833-200-7366	1-402-896-3774	1-866-312-4206
Hours:	8 AM to 8 PM ET, Monday-Friday	8 AM to 8 PM ET, Monday-Friday	8 AM to 8 PM ET, Monday-Friday
ePrescribe to:	ARx Patient Solutions	Amber Specialty Pharmacy	PANTHERx Specialty Pharmacy
Address:	4500 W 107th Street Overland Park, KS 66207	10004 South 152nd Street Omaha, NE 68138	24 Summit Park Drive Pittsburgh, PA 15275
NCPDP #:	1720677	2815338	3997117



Scan the QR code to start your
patients on TAVNEOS® today

PLEASE NOTE: TAVNEOS® is a limited-distribution specialty product available commercially to patients only through select Specialty Pharmacy providers. Once all information is obtained and appropriate patient support is provided, the TAVNEOS® Connect Team will transfer the enrollment and Rx to the associated specialty pharmacy for continued support toward prescription fulfillment.

For questions, call the TAVNEOS® Connect Team at **1-833-TAVNEOS (1-833-828-6367)**
and choose option 2, Monday through Friday from 8 AM to 8 PM ET

Patients and healthcare providers may not seek reimbursement for, transfer, or sell product provided through Amgen support programs. Amgen reserves the right to change, modify, or discontinue the program at any time.

References: 1. Data on file, Amgen; [1]; 2023. 2. Data on file, Amgen; [2]; 2023.



© 2023 Amgen Inc. All rights reserved. USA-569-80358

